Drugs / SoC systemic therapy
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05222087 Background | Jan 2022 → Apr 2025 overdue | non-small cell lung carcinoma | Peter MacCallum Cancer Centre, Australia | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SoC systemic therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05222087 ↗ |
| Route | Intravenous | “Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles” NCT05222087 ↗ |